AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic <i>IDH2</i> MutationsKatharine Yen, Shinsan M. Su, Byron DeLaBarre et al.|Cancer Discovery|2017Cited by 457
A mouse model of a human congenital disorder of glycosylation caused by loss of PMM2Barden Chan, Shengfang Jin, Michelle Clasquin et al.|Human Molecular Genetics|2016Cited by 47
Effects of AG-348, a Pyruvate Kinase Activator, on Anemia and Hemolysis in Patients with Pyruvate Kinase Deficiency: Data from the DRIVE PK StudyRachael F. Grace, Bertil Glader, Christian Rosé et al.|Blood|2016Cited by 6
Supplementary Methods from AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic <i>IDH2</i> MutationsKatharine Yen, Shinsan M. Su, Jeremy Travins et al.|Unknown|2023Cited by 0